Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Cell. Infect. Microbiol.

Sec. Molecular Bacterial Pathogenesis

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1674534

This article is part of the Research TopicCarbapenem-Resistant Enterobacteriaceae: Microbiome Influence and Infectious Disease DynamicsView all 3 articles

The Potential of the Microbiome as a Target for Prevention and Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Provisionally accepted
Lu  ZhangLu ZhangTinghui  XuTinghui XuWenqian  ChenWenqian ChenYinying  ChaiYinying ChaiYi  WuYi WuXinghai  DuXinghai Du*
  • Zhejiang Chinese Medical University, Hangzhou, China

The final, formatted version of the article will be published soon.

Carbapenem-resistant Enterobacteriaceae (CRE) present an escalating threat to global health due to their high transmissibility, limited treatment options, and high mortality rates. The gastrointestinal tract serves as both a major reservoir and a transmission hub for CRE, especially under conditions of antibiotic-induced dysbiosis. This review highlights the growing interest in the gut microbiome as a potential target for preventing and managing CRE infections. Building upon the understanding of CRE pathogenesis, we examine how commensal microbiota contribute to colonization resistance through mechanisms such as nutrient competition, spatial niche exclusion, immune modulation, and the production of antimicrobial metabolites. We further discuss microbiome-based therapeutic strategies, including probiotic administration, fecal microbiota transplantation (FMT), and supplementation with short-chain fatty acids (SCFAs), that have shown encouraging results in reducing intestinal CRE colonization. In addition, we explore emerging microbiome engineering approaches, particularly CRISPR-Cas9-mediated systems, which enable the selective elimination of resistant strains while maintaining microbial homeostasis. Current microbiome-based approaches have shown promise in the treatment and prevention of CRE infections, but further research is still needed to clarify their mechanisms, evaluate long-term safety, and determine their effectiveness in different clinical settings. With continued studies and thoughtful integration into existing infection control and antibiotic stewardship practices, these strategies may gradually contribute to a more practical and sustainable way to manage CRE.

Keywords: Carbapenem-resistant Enterobacteriaceae1, gut microbiota2, Colonization resistance3, Microbiome-targeted therapy4, probiotics5, Fecal microbiota transplantation6, Short-chain fatty acids7

Received: 28 Jul 2025; Accepted: 24 Sep 2025.

Copyright: © 2025 Zhang, Xu, Chen, Chai, Wu and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xinghai Du, duxinghai16@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.